BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 21452186)

  • 1. Role of endonucleases XPF and XPG in nucleotide excision repair of platinated DNA and cisplatin/oxaliplatin cytotoxicity.
    Graf N; Ang WH; Zhu G; Myint M; Lippard SJ
    Chembiochem; 2011 May; 12(7):1115-23. PubMed ID: 21452186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Base excision repair of reactive oxygen species-initiated 7,8-dihydro-8-oxo-2'-deoxyguanosine inhibits the cytotoxicity of platinum anticancer drugs.
    Preston TJ; Henderson JT; McCallum GP; Wells PG
    Mol Cancer Ther; 2009 Jul; 8(7):2015-26. PubMed ID: 19567822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monofunctional platinum-DNA adducts are strong inhibitors of transcription and substrates for nucleotide excision repair in live mammalian cells.
    Zhu G; Myint M; Ang WH; Song L; Lippard SJ
    Cancer Res; 2012 Feb; 72(3):790-800. PubMed ID: 22180496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. XPF protein levels determine sensitivity of malignant melanoma cells to oxaliplatin chemotherapy: suitability as a biomarker for patient selection.
    Hatch SB; Swift LP; Caporali S; Carter R; Hill EJ; MacGregor TP; D'Atri S; Middleton MR; McHugh PJ; Sharma RA
    Int J Cancer; 2014 Mar; 134(6):1495-503. PubMed ID: 23982883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of domains for protein-protein interaction of nucleotide excision repair proteins modifies cancer cell sensitivity to platinum derivatives and genomic stability.
    Jordheim LP; Cros-Perrial E; Matera EL; Bouledrak K; Dumontet C
    Clin Exp Pharmacol Physiol; 2014 Oct; 41(10):817-24. PubMed ID: 25115435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficient nucleotide excision repair of cisplatin, oxaliplatin, and Bis-aceto-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts.
    Reardon JT; Vaisman A; Chaney SG; Sancar A
    Cancer Res; 1999 Aug; 59(16):3968-71. PubMed ID: 10463593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Downregulation of XPF-ERCC1 enhances cisplatin efficacy in cancer cells.
    Arora S; Kothandapani A; Tillison K; Kalman-Maltese V; Patrick SM
    DNA Repair (Amst); 2010 Jul; 9(7):745-53. PubMed ID: 20418188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unexpected Growth-Promoting Effect of Oxaliplatin in Excision Repair Cross-Complementation Group 1 Transfected Human Colon Cancer Cells.
    Jordheim LP; Chettab K; Cros-Perrial E; Matera EL; Dumontet C
    Pharmacology; 2018; 102(3-4):161-168. PubMed ID: 30048976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trabectedin and its C subunit modified analogue PM01183 attenuate nucleotide excision repair and show activity toward platinum-resistant cells.
    Soares DG; Machado MS; Rocca CJ; Poindessous V; Ouaret D; Sarasin A; Galmarini CM; Henriques JA; Escargueil AE; Larsen AK
    Mol Cancer Ther; 2011 Aug; 10(8):1481-9. PubMed ID: 21622731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro studies on the mechanisms of oxaliplatin resistance.
    Hector S; Bolanowska-Higdon W; Zdanowicz J; Hitt S; Pendyala L
    Cancer Chemother Pharmacol; 2001 Nov; 48(5):398-406. PubMed ID: 11761458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Killing of chronic lymphocytic leukemia by the combination of fludarabine and oxaliplatin is dependent on the activity of XPF endonuclease.
    Zecevic A; Sampath D; Ewald B; Chen R; Wierda W; Plunkett W
    Clin Cancer Res; 2011 Jul; 17(14):4731-41. PubMed ID: 21632856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the DNA Repair Endonuclease ERCC1-XPF with Green Tea Polyphenol Epigallocatechin-3-Gallate (EGCG) and Its Prodrug to Enhance Cisplatin Efficacy in Human Cancer Cells.
    Heyza JR; Arora S; Zhang H; Conner KL; Lei W; Floyd AM; Deshmukh RR; Sarver J; Trabbic CJ; Erhardt P; Chan TH; Dou QP; Patrick SM
    Nutrients; 2018 Nov; 10(11):. PubMed ID: 30400270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Defects in interstrand cross-link uncoupling do not account for the extreme sensitivity of ERCC1 and XPF cells to cisplatin.
    De Silva IU; McHugh PJ; Clingen PH; Hartley JA
    Nucleic Acids Res; 2002 Sep; 30(17):3848-56. PubMed ID: 12202770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genome-wide identification of genes conferring resistance to the anticancer agents cisplatin, oxaliplatin, and mitomycin C.
    Wu HI; Brown JA; Dorie MJ; Lazzeroni L; Brown JM
    Cancer Res; 2004 Jun; 64(11):3940-8. PubMed ID: 15173006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transcription inhibition by platinum-DNA cross-links in live mammalian cells.
    Ang WH; Myint M; Lippard SJ
    J Am Chem Soc; 2010 Jun; 132(21):7429-35. PubMed ID: 20443565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel trinuclear platinum complex overcomes cisplatin resistance in an osteosarcoma cell system.
    Perego P; Caserini C; Gatti L; Carenini N; Romanelli S; Supino R; Colangelo D; Viano I; Leone R; Spinelli S; Pezzoni G; Manzotti C; Farrell N; Zunino F
    Mol Pharmacol; 1999 Mar; 55(3):528-34. PubMed ID: 10051537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acquired resistance to oxaliplatin is not directly associated with increased resistance to DNA damage in SK-N-ASrOXALI4000, a newly established oxaliplatin-resistant sub-line of the neuroblastoma cell line SK-N-AS.
    Saintas E; Abrahams L; Ahmad GT; Ajakaiye AM; AlHumaidi AS; Ashmore-Harris C; Clark I; Dura UK; Fixmer CN; Ike-Morris C; Mato Prado M; Mccullough D; Mishra S; Schöler KM; Timur H; Williamson MD; Alatsatianos M; Bahsoun B; Blackburn E; Hogwood CE; Lithgow PE; Rowe M; Yiangou L; Rothweiler F; Cinatl J; Zehner R; Baines AJ; Garrett MD; Gourlay CW; Griffin DK; Gullick WJ; Hargreaves E; Howard MJ; Lloyd DR; Rossman JS; Smales CM; Tsaousis AD; von der Haar T; Wass MN; Michaelis M
    PLoS One; 2017; 12(2):e0172140. PubMed ID: 28192521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of small molecule inhibitors of ERCC1-XPF that inhibit DNA repair and potentiate cisplatin efficacy in cancer cells.
    Arora S; Heyza J; Zhang H; Kalman-Maltese V; Tillison K; Floyd AM; Chalfin EM; Bepler G; Patrick SM
    Oncotarget; 2016 Nov; 7(46):75104-75117. PubMed ID: 27650543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced nucleotide excision repair in cisplatin resistant human KB carcinoma cells.
    Mukai M; Kanzaki A; Chen ZS; Miyashita H; Sumizawa T; Furukawa T; Haraguchi M; Takebayashi Y; Takamatsu H; Akiyama S
    Oncol Rep; 2002; 9(4):839-44. PubMed ID: 12066219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A scanning-to-incision switch in TFIIH-XPG induced by DNA damage licenses nucleotide excision repair.
    Bralić A; Tehseen M; Sobhy MA; Tsai CL; Alhudhali L; Yi G; Yu J; Yan C; Ivanov I; Tsutakawa SE; Tainer JA; Hamdan SM
    Nucleic Acids Res; 2023 Feb; 51(3):1019-1033. PubMed ID: 36477609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.